Elan Seeks Arbitration With Pfizer Over Alzheimer Research

Law360, New York (December 11, 2003, 12:00 AM EST) -- Irish drug maker Elan is seeking binding arbitration in a dispute with Pfizer over research into treating Alzheimer's disease, the company said Friday.

The dispute concerns a research, development and marketing agreement, originally entered into with Pharmacia in August 2000. The research centered on the discovery of small molecule inhibitors of beta secretase at the research stage for the treatment of Alzheimer's disease, according to Elan.

The Irish drug maker said it had taken the step following the termination of an agreement with Pfizer to jointly...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.